Carolinas HealthCare System

Research and Clinical Trials

Other Hematopoietic 

Brief Description Principal Investigator
The purpose of this study is to compare the effectiveness of CMX001 to placebo for the prevention of CMV infection in stem cell transplant patients who do not have CMV before starting treatment with CMX001.


Shahid, Zainab 
To evaluate the efficacy of brincidofovir (BCV) for the treatment of adenovirus (AdV) infection in patients at risk of AdV infection progression and in patients who have localized or disseminated AdV disease. Eckrich, Michael James 
Complete response of VOD [ Time Frame: D+100 from SCT or 100 days from start of chemotherapy] Gilman, Andrew Lee 
Describe the clinical burden of polycythemia vera (PV)
Describe healthcare resource utilization associated with the management of PV
Grunwald, Michael Richard 
To determine the ability of CD34+ cell selection using the CliniMACS® device as the sole
GVHD prophylaxis to prevent severe (grade III-IV) acute GVHD in recipients of
alternative donor (mismatched related donor and unrelated donor) hematopoietic stem
cell transplants.
Gilman, Andrew Lee 
To assess the ability of a donor lymphocyte infusion given with methotrexate GVHD prophylaxis to accelerate immune recovery following transplantation of a CD34+selected, T cell-depleted stem cell product. Gilman, Andrew Lee 
Primary:
To collect high quality specimens from patients with hematologic disorders and normal volunteers.
Exploratory:
Future specimen analyses will be performed to determine the differences between sick and normal cells. Data used for these comparisons will include, but are not limited to: gene expression data, DNA, RNA, epigenetics, proteomics, metabolomics, and pathway analysys.
Avalos, Belinda Rene 
Number of patients with overall hematologic response, Complete response, very good partial response and partial response

2-year vital organ deterioration and mortality rate. Rate of hospitalization for congestive heart failure or progression to end stage renal disease or death at 2 years
Bhutani, Manisha 
The purpose of this study is to determine if treatment with alemtuzumab, fludarabine and melphalan followed by related/unrelated bone marrow, peripheral blood stem cell, or umbilical cord blood cell transplant will result in donor engraftment on day +100. It is also to determine major toxicities from this conditioning regimen, within the first 100 days after transplantation. Gilman, Andrew Lee 
About Carolinas HealthCare System
Who We Are
Leadership
Community Benefit
Corporate Financial Information
Diversity & Inclusion
Annual Report
Foundation
Patient Links
Pay Your Bill
Hospital Pre-Registration
Patient Rights
Privacy
Financial Assistance
Quality & Value Reports
Insurance
Careers
Join Carolinas HealthCare System
Physician Careers

For Employees
Carolinas Connect
Connect with Us
Watch Carolinas HealthCare on YoutubeFollow Carolinas HealthCare on TwitterLike Carolinas HealthCare on FacebookContact Carolinas HealthCareJoin Carolinas HealthCare on LinkedInGo to our mobile website.